155 related articles for article (PubMed ID: 23824179)
1. Cutaneous side effects of vemurafenib: a case report and discussion.
Shea SM; Boyd K; Patterson J
Wien Med Wochenschr; 2013 Aug; 163(15-16):376-9. PubMed ID: 23824179
[TBL] [Abstract][Full Text] [Related]
2. A model for cutaneous squamous cell carcinoma in vemurafenib therapy.
Kent R; Glorioso S; Nordberg ML
J La State Med Soc; 2012; 164(6):311-3. PubMed ID: 23431672
[TBL] [Abstract][Full Text] [Related]
3. Lupus erythematosus-like skin eruption after vemurafenib therapy.
Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M
J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748
[No Abstract] [Full Text] [Related]
4. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib-induced granuloma annulare.
Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
[No Abstract] [Full Text] [Related]
9. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
[No Abstract] [Full Text] [Related]
10. Analysis of dermatologic events in vemurafenib-treated patients with melanoma.
Lacouture ME; Duvic M; Hauschild A; Prieto VG; Robert C; Schadendorf D; Kim CC; McCormack CJ; Myskowski PL; Spleiss O; Trunzer K; Su F; Nelson B; Nolop KB; Grippo JF; Lee RJ; Klimek MJ; Troy JL; Joe AK
Oncologist; 2013; 18(3):314-22. PubMed ID: 23457002
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
12. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
13. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
15. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
[TBL] [Abstract][Full Text] [Related]
16. [Vemurafenib (Zelboraf) in the therapy of melanoma].
Liszkay G
Magy Onkol; 2013 Jun; 57(2):110-3. PubMed ID: 23795356
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous adverse events during vemurafenib therapy.
Chandrakumar SF; Yeung J
J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
[TBL] [Abstract][Full Text] [Related]
19. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
20. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
